Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Abbott creates one molecule with two antibody functions

Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.

19 Oct 2007

AngioGenex files patent on first small molecule Id-inhibitors

AngioGenex Inc. has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins.

17 Oct 2007

Researchers specifically manipulate tumor angiogenesis gene

Angiogenesis is a common process that is essential for tumor growth beyond 2 mm. Although numerous growth factors are involved, vascular endothelial growth factor (VEGF), particularly VEGF-A, has been shown to play an important role in tumor angiogenesis.

16 Oct 2007

Important insights into blood vessel formation

Researchers have identified a molecular pathway that plays a critical role in the growth of blood vessels.

15 Oct 2007

Rapamycin and Gleevec reverses effects of portal hypertension in rats

A combined treatment with rapamycin and Gleevec might reverse the effects of portal hypertension in patients with chronic liver disease, according to the results of a new study on rats.

2 Oct 2007

Survival data presented from phase II study of hormone-resistant prostate cancer patients

The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).

26 Sep 2007

New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastases

New Phase II data suggests that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.

26 Sep 2007

Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer

Researchers in Portugal have discovered that a specific mutation of the COX2 gene seems to play a role in the onset of ovarian cancer, increasing women's susceptibility to developing the disease.

26 Sep 2007

FDA fast tracks PI-88 for the treatment of post resection liver cancer

Progen Pharmaceuticals Limited has announced that its investigational anti-cancer drug PI-88 has been awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

25 Sep 2007

Does physical activity provide a molecular key to longevity?

Fitness and physical exercise are among the most neglected means to improve prognosis. They are the healthiest cardiovascular intervention. Even cardiologists focus on pharmacological treatment and evaluate classical risk factors without asking about daily exercise or objective measures of physical capacity. It is surprising considering the strong data that underscores the survival benefit of regular exercise training.

2 Sep 2007

Blocking angiogenesis signaling from inside cell may lead to serious health problems

Angiogenesis inhibitors that block a tumor's development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy.

24 Aug 2007

New pathway for inflammation-induced cancer

A well-known inflammatory protein spawns an enzyme that inactivates two tumor-suppressing genes, ultimately triggering production of new blood vessels to nourish breast cancer cells, researchers at The University of Texas M. D. Anderson Cancer Center report in the August edition of the journal Cell .

11 Aug 2007

Protein kinase G holds promise for cancer treatment

An enzyme that cancer cells eliminate, apparently so they can keep proliferating, may hold clues to more targeted, effective cancer treatment, scientists say.

19 Jul 2007

Peregrine licenses worldwide rights to a novel anti-angiogenesis technology

Peregrine Pharmaceuticals, Inc. has announced that it has licensed worldwide exclusive rights to a novel anti-angiogenesis technology from The University of Texas M. D. Anderson Cancer Center.

10 Jul 2007

Biomira files NDA for novel inhibitor of hypoxia-inducible factor-1 alpha

Biomira Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for PX-478. PX-478 has been shown in preclinical studies to inhibit hypoxia-inducible factor (HIF)-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival.

4 Jul 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007